Himalaya Therapeutics
https://www.himalayatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Himalaya Therapeutics
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice